everest-medicine-logo.jpg
Everest Medicines Announces Positive Results of In Vitro Study of Xerava™ (eravacycline) Against Human Mycoplasmas
June 22, 2020 19:00 ET | Everest Medicines
Xerava demonstrated greater potency against a select group of mycoplasma species in comparison to four other antimicrobials Data suggest Xerava may provide alternative treatment option for some...
everest-medicine-logo.jpg
云顶新耀宣布Xerava™(依拉环素)针对人类支原体的体外研究取得重大进展
June 22, 2020 19:00 ET | Everest Medicines
与其他四种抗生素相比,依拉环素对特定的支原体亚群拥有更强的抗菌效果 数据表明,对药物敏感和耐药的支原体引起的一些呼吸道感染,依拉环素可能提供了替代治疗方案 中国上海, June 23, 2020 (GLOBE NEWSWIRE) -- 云顶新耀(Everest...
everest-medicine-logo.jpg
Everest Medicines Completes US$310 Million Series C Financing
June 04, 2020 20:15 ET | Everest Medicines
SHANGHAI, China, June 04, 2020 (GLOBE NEWSWIRE) -- Everest Medicines, a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address...
everest-medicine-logo.jpg
云顶新耀完成3.1亿美元C轮融资
June 04, 2020 20:15 ET | Everest Medicines
中国上海, June 05, 2020 (GLOBE NEWSWIRE) -- 云顶新耀(Everest Medicines),一家专注于创新药开发及商业化的生物制药公司,致力于满足中国(含香港特别行政区、澳门特别行政区以及台湾地区)及其它亚洲市场未满足的医疗需求,今天宣布完成3.1亿美元C轮融资。 ...
everest-medicine-logo.jpg
CORRECTION: Everest Medicines Announces That Licensing Partner Immunomedics has Received FDA Accelerated Approval for Trodelvy (sacituzumab govitecan-hziy) in Previously-treated Metastatic Triple-Negative Breast Cancer
April 24, 2020 21:15 ET | Everest Medicines
SHANGHAI, China, April 24, 2020 (GLOBE NEWSWIRE) -- In a release issued under the same headline on Friday, April 24th by Everest Medicines (Nasdaq: IMMU), at the end of the subheading, please note...
everest-medicine-logo.jpg
云顶新耀宣布其授权合作伙伴Immunomedics新药Trodelvy (sacituzumab govitecan-hziy)获得美国食品药物管理局加速上市批准,用于既往治疗无效的转移性三阴性乳腺癌患者
April 24, 2020 21:15 ET | Everest Medicines
中国上海, April 24, 2020 (GLOBE NEWSWIRE) -- 家专注于创新药开发及商业化的生物制药公司,致力于满足中国(含香港特别行政区、澳门特别行政区以及台湾地区)及其它亚洲市场未满足的医疗需求,今天宣布美国食品药物管理局(FDA)已批准Immunomedics Inc. ( 纳斯达克股票代码:IMMU)提交的sacituzumab...
everest-medicine-logo.jpg
Everest Medicines Announces That Licensing Partner Immunomedics has Received FDA Accelerated Approval for Trodelvy (sacituzumab govitecan-hziy) in Previously-treated Metastatic Triple-Negative Breast Cancer
April 24, 2020 07:00 ET | Everest Medicines
SHANGHAI, China, April 24, 2020 (GLOBE NEWSWIRE) -- Everest Medicines, a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address...
everest-medicine-logo.jpg
云顶新耀宣布其授权合作伙伴Immunomedics新药Trodelvy (sacituzumab govitecan-hziy)获得美国食品药物管理局加速上市批准,用于既往治疗无效的转移性三阴性乳腺癌患者
April 24, 2020 07:00 ET | Everest Medicines
中国上海, April 24, 2020 (GLOBE NEWSWIRE) -- 家专注于创新药开发及商业化的生物制药公司,致力于满足中国(含香港特别行政区、澳门特别行政区以及台湾地区)及其它亚洲市场未满足的医疗需求,今天宣布美国食品药物管理局(FDA)已批准Immunomedics Inc. ( 纳斯达克股票代码:IMMU)提交的sacituzumab...
everest-medicine-logo.jpg
Everest Medicines Announces Approval of Clinical Trial Application by China National Medical Products Administration to Initiate China Registration Study of Sacituzumab Govitecan for the Treatment of Metastatic Triple-Negative Breast Cancer
April 22, 2020 08:00 ET | Everest Medicines
Approval allows Everest Medicines to enroll patients in registration clinical study in ChinaThe US FDA granted Fast Track Designation and Breakthrough Therapy Designation to sacituzumab govitecan for...
everest-medicine-logo.jpg
云顶新耀宣布中国国家药品监督管理局批准sacituzumab govitecan临床试验申请, 将启动治疗转移性三阴性乳腺癌中国注册临床研究
April 22, 2020 08:00 ET | Everest Medicines
此项临床试验的获批允许云顶新耀将患者纳入中国注册临床研究美国食品和药物管理局已授予sacituzumab govitecan 快速审定通道与突破性疗法认定,用于既往治疗无效的转移性三阴性乳腺癌患者 中国上海, April 22, 2020 (GLOBE NEWSWIRE) -- 中国上海 – 2020年4月22日 – 云顶新耀(Everest...